9 Alzheimer's Meds Of The Future

That Are Here Now



Thinking about getting Alzheimer’s disease is scary—for the afflicted and those who see at best a challenge in caring for the sufferer’s unyielding needs. It’s also scary to think about Alzheimer’s because it is one of the few killers today in the face of which we seem helpless.

At a time when we are seeing declines in heart disease and certain cancer deaths, Alzheimer’s rates have increased 71% since 2000 and the aging boomers are prime candidates to treble these numbers.

5.3 million Americans are in the grips of the third leading cause of death (topped only by cancer and heart disease). By 2050, the number of people age 65 and older with Alzheimer’s is estimated to nearly triple to 13.8 million.

Dementia Cost

The Alzheimer’s Association says Medicare spending for these patients with the disease or simple dementia is 3x higher than for seniors without dementia. Medicaid payments are 19x higher. Despite these pessimistic trends, findings suggest the earlier we intervene in the process and with the right drugs, nutrients and safe medical procedures, this could become a preventable disease.

Here's What Researchers Are Looking At And What Can You Do Now:

EPPS. Korean scientists reported in the December 8, 2015 issue of Nature Communications that EPPS, a taurine-like molecule, added to the drinking water of mice bred to develop Alzheimer’s, washed away the protein plaques associated with the disease and enhanced learning and memory functions. EPPS is short for 4-(2-hydroxyethyl)-1- piperazinepropanesulphonic acid. It is safe at high doses. EPPS attaches to amyloid-beta clumps and breaks them up into smaller molecules. Even when delivered in drinking water, EPPS can still reach the organ and cross the protective blood-brain barrier.

What you can do now: EPPS isn’t readily available to the public. One can take added doses of the amino acid taurine, cited in the study for also breaking up brain plaque, though not as significantly. The researchers explain that before the effects of the disease are seen some 10 to 15 years or more of plaque build-up ensue, so the earlier one starts to prevent this disease, the better the outcome will be, making the case for early use of taurine. This amino acid is frequently put into energy drinks. Mayo Clinic advises safe doses of up to 3,000 milligrams daily.

Aducanumab. A human monoclonal antibody, also known as BIIB037, developed by Biogen Idec, this drug’s results were reported at the 12th International Conference on Alzheimer’s and Parkinsons’s Diseases and Related Neurological Disorders (AD/PD 2015), in Nice, France, in March 2015. In a phase one randomized, placebo-controlled trial treated patients up to 54 weeks showed plaque reductions and slower deterioration. Higher doses worked better.

What you can do now: This study is currently recruiting volunteers. Contact Biogen at clinicaltrials@biogen.com.

Solanezumab. Eli Lilly’s solanezumab is in phase 3 clinical trials with patients. It slowed disease progression by about 30% over 3 years. The scientists doing their work at 69 multiple locations believe that if given earlier in people’s lives, the effects would be greater. Solanezumab is an antibody that attacks plaque and breaks it up. We should know more this year about the latest trial outcome.
What you can do now: There are at least two trials actively recruiting for this drug. Call Eli Lilly at 1-877-285-4559 for more information.

Alzheimer’s Chocolate Drug

Ultrasound. Australian scientists have used ultrasound to dissolve brain plaque in an experimental study but the technology has not yet begun clinical trials. “We’re extremely excited by this innovation of treating Alzheimer’s without using drug therapeutics,” Professor Jürgen Götz told the medical media. “The ultrasound waves oscillate tremendously quickly, activating microglial cells that digest and remove the amyloid plaques that destroy brain synapses. This treatment restored memory function to the same level of normal healthy mice.” This is not yet available for human trials.

Brain fungus. Alois Alzheimer said fungus caused his disease as early as 1910. Doug Kaufmann has authored a series of books on the fungal link to disease and discussed this connection thoroughly. “Unfortunately, neurologists are totally unaware that certain common fungi (one being penicillin) are neurotoxic, and therefore fully capable of causing the symptoms seen in neurodegenerative diseases, like Alzheimer’s disease.” A study in the journal Scientific Reports notes of 21 cadavers’ brain tissues and blood tissues were examined for the presence of disease causing fungi. The tissues of 11 patients who died of Alzheimer’s disease all had fungi. 10 control patients who did not die of Alzheimer’s disease had no signs of these fungi in their blood stream or brains. Kaufmann says, “I can assure you that more research will confirm what this paper already has confirmed; that Alzheimer’s disease is one of many, many fungal diseases. Is it now time for sufferers to wait until future researchers confirm this work, or do we owe it to every Alzheimer’s patient in the world, to immediately initiate an antifungal program for them based on this report? What do you suppose will help an Alzheimer’s patient more; an antifungal medication and a changed diet for a few weeks to see if they are on the right track in reversing the disease…or doing nothing?”

What you can do now: Kaufmann has developed an anti-fungal diet. There are already many anti-fungal drug treatments available for various conditions and one of these could be adapted in order to treat or slow down the progression of Alzheimer’s.

Metformin. This long-time diabetes drug is also being examined for heading off Alzheimer’s disease with a clinical trial as an anti-ager that was approved for start in 2016. Metformin appears to work like a systemic anti-inflammatory and is being studied against cancer, diabetes and Alzheimer’s.

What you can do now: Metformin can be prescribed by your doctor, but only if a patient is diabetic or close to prediabetic state.

Smell Test For Alzheimer's

Distilled water. A diet of distilled water was also shown to clear up amyloid plaque. Researchers trying to study a nontoxic method for reducing cholesterol discovered a novel inexpensive method for decreasing Alzheimer’s risk. The increased circulating cholesterol, thought to cause coronary artery disease, is also a cause of production and accumulation of amyloid beta (Abeta) plaque. The study “yielded a statistically significant approximately 28% reduction due to the use of distilled water. These findings suggest that water quality may impact on human health in the setting of increased circulating cholesterol levels, and could illustrate a truly simple life-style change that could be of benefit in AD.”

What you can do now: Distilled water can be purchased bottled or produced at home. Look for units such as at Waterwise.com.

Turmeric. The consumption of curry, which is made from turmeric, a source of curcumin, could also be an Alzheimer’s preventive. Curcumin is an anti-inflammatory phytochemical that is found in the turmeric root. It is the main component in curry and being studied for prevention of the disease.

What you can do now: Either eat lots of curry or look for supplements such as BCM-95 as a particularly well absorbed form.

Systemic enzymes. A combination of two enzymes, recommended for circulatory health, might become a preventive supplement against Alzheimer’s disease. Serrapeptase (SP) and nattokinase (NK) counter chronic damage characterized by increases in brain acetylcholinesterase (AchE) activity, transforming growth factor β (TGF-β) Fas and interleukin-6 (IL-6) levels and decreases in brain-derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1). Also, a decline in the expression levels of disintegrin and metalloproteinase domain 9 (ADAM9) genes in the brain is reduced.

Oral administration of SP or NK for 45 days resulted in a significant decrease in brain AchE activity, TGF-β, Fas and IL-6 levels. Treatment led to increases in BDNF and IGF-1. SP and NK increased the expression levels of ADAM9 and ADAM10 genes in the brain tissue. These findings “support our hypothesis that the oral administration of proteolytic enzymes, SP and/or NK, would have an effective role in modulating certain factors characterizing AD. Thus, these enzymes may have a therapeutic application in the treatment of AD.”

Fadl NN, Ahmed HH, Booles HF, Sayed AH.Serrapeptase and nattokinase intervention for relieving Alzheimer’s disease pathophysiology in rat model. Hum Exp Toxicol. 2013 Jul;32(7):721-35. doi: 10.1177/0960327112467040.
Sparks DL, Lochhead J, Horstman D, Wagoner T, Martin T. Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer amyloid beta (Abeta) in rabbit brain. J Alzheimers Dis. 2002 Dec;4(6):523-9.
Sparks DL, Lochhead J, Horstman D, Wagoner T, Martin T. Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer amyloid beta (Abeta) in rabbit brain. J Alzheimers
comments powered by Disqus